急性缺血性卒中血管内取栓术后强化与常规降压比较:OPTIMAL-BP随机临床试验
OPTIMAL-BP为多中心、随机、开放标签、盲法终点评估试验,在韩国19个卒中中心纳入306例大血管闭塞急性缺血性卒中且改良脑梗死溶栓(mTICI)评分≥2b(部分或完全再通)的患者,随机接受强化降压(收缩压目标<140 mmHg,n=155)或常规降压(收缩压目标140-180 mmHg,n=150)24小时。主要终点为3个月功能独立(改良Rankin量表评分0-2),强化组39.4%低于常规组54.4%,风险差-15.1%(95%CI -26.2%至-3.9%),校正OR 0.56(95%CI 0.33-0.96;P=0.03)。症状性颅内出血强化组9.0% vs 常规组8.1%(风险差1.0%[95%CI -5.3%至7.3%];校正OR 1.10[95%CI 0.48-2.53];P=0.82),3个月内与索引卒中相关死亡强化组7.7% vs 常规组5.4%(风险差2.3%[95%CI -3.3%至7.9%];校正OR 1.73[95%CI 0.61-4.92];P=0.31)。作者结论认为取栓成功再通后应避免强化降压。
要点
- 取栓成功再通(mTICI≥2b)后24小时强化降压(收缩压<140 mmHg)较常规降压(140-180 mmHg)降低3个月功能独立率(39.4% vs 54.4%,校正OR 0.56,P=0.03)。
- 症状性颅内出血强化组9.0% vs 常规组8.1%(校正OR 1.10,P=0.82),无统计学显著差异。
- 3个月内索引卒中相关死亡强化组7.7% vs 常规组5.4%(校正OR 1.73,P=0.31),无统计学显著差异。
- 试验因数据与安全监查委员会提出安全担忧而提前终止。
- 作者认为急性缺血性卒中取栓成功再通后应避免强化降压。
适用人群与场景
- 韩国19个卒中中心纳入的大血管闭塞急性缺血性卒中患者,接受血管内取栓且改良脑梗死溶栓(mTICI)评分≥2b(部分或完全再通)。
- 随机分组后24小时内接受强化或常规血压管理。
诊断标准与关键阈值
- 再通标准:改良脑梗死溶栓(mTICI)评分≥2b(部分或完全再通)。
- 强化降压目标:收缩压<140 mmHg。
- 常规降压目标:收缩压140-180 mmHg。
处置流程与药物剂量
- 取栓成功再通后24小时内,强化降压组收缩压目标<140 mmHg(n=155)。
- 取栓成功再通后24小时内,常规降压组收缩压目标140-180 mmHg(n=150)。
红旗征与不能漏的情况
- 试验因数据与安全监查委员会提出安全担忧而提前终止。
研究设计与关键结果
- 多中心、随机、开放标签、盲法终点评估试验,在韩国19个卒中中心于2020年6月至2022年11月纳入306例患者(最终随访2023年3月8日),随机分为强化降压组(收缩压<140 mmHg,n=155)和常规降压组(收缩压140-180 mmHg,n=150),干预24小时。
- 306例随机患者中305例确认符合条件,302例(99.0%)完成试验;平均年龄73.0岁;女性122例(40.4%)。
- 主要终点3个月功能独立(改良Rankin量表评分0-2):强化组39.4% vs 常规组54.4%,风险差-15.1%(95%CI -26.2%至-3.9%),校正OR 0.56(95%CI 0.33-0.96;P=0.03)。
- 主要安全终点症状性颅内出血(36小时内):强化组9.0% vs 常规组8.1%,风险差1.0%(95%CI -5.3%至7.3%),校正OR 1.10(95%CI 0.48-2.53;P=0.82)。
- 主要安全终点3个月内索引卒中相关死亡:强化组7.7% vs 常规组5.4%,风险差2.3%(95%CI -3.3%至7.9%),校正OR 1.73(95%CI 0.61-4.92;P=0.31)。
证据类型、等级与局限
- 证据类型:多中心随机对照试验(RCT)。
- 局限:试验因数据与安全监查委员会提出安全担忧而提前终止;原文未报告其他局限性。
对床旁实践的改变
- 对于大血管闭塞急性缺血性卒中经血管内取栓成功再通(mTICI≥2b)的患者,强化降压(收缩压<140 mmHg)24小时较常规降压(140-180 mmHg)降低3个月功能独立率,作者认为应避免强化降压。
指南或共识出处
- OPTIMAL-BP随机临床试验(ClinicalTrials.gov标识符:NCT04205305)。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Optimal blood pressure (BP) control after successful reperfusion with endovascular thrombectomy (EVT) for patients with acute ischemic stroke is unclear.
OBJECTIVE: To determine whether intensive BP management during the first 24 hours after successful reperfusion leads to better clinical outcomes than conventional BP management in patients who underwent EVT.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label trial with a blinded end-point evaluation, conducted across 19 stroke centers in South Korea from June 2020 to November 2022 (final follow-up, March 8, 2023). It included 306 patients with large vessel occlusion acute ischemic stroke treated with EVT and with a modified Thrombolysis in Cerebral Infarction score of 2b or greater (partial or complete reperfusion).
INTERVENTIONS: Participants were randomly assigned to receive intensive BP management (systolic BP target <140 mm Hg; n = 155) or conventional management (systolic BP target 140-180 mm Hg; n = 150) for 24 hours after enrollment.
MAIN OUTCOMES AND MEASURES: The primary outcome was functional independence at 3 months (modified Rankin Scale score of 0-2). The primary safety outcomes were symptomatic intracerebral hemorrhage within 36 hours and death related to the index stroke within 3 months.
RESULTS: The trial was terminated early based on the recommendation of the data and safety monitoring board, which noted safety concerns. Among 306 randomized patients, 305 were confirmed eligible and 302 (99.0%) completed the trial (mean age, 73.0 years; 122 women [40.4%]). The intensive management group had a lower proportion achieving functional independence (39.4%) than the conventional management group (54.4%), with a significant risk difference (-15.1% [95% CI, -26.2% to -3.9%]) and adjusted odds ratio (0.56 [95% CI, 0.33-0.96]; P = .03). Rates of symptomatic intracerebral hemorrhage were 9.0% in the intensive group and 8.1% in the conventional group (risk difference, 1.0% [95% CI, -5.3% to 7.3%]; adjusted odds ratio, 1.10 [95% CI, 0.48-2.53]; P = .82). Death related to the index stroke within 3 months occurred in 7.7% of the intensive group and 5.4% of the conventional group (risk difference, 2.3% [95% CI, -3.3% to 7.9%]; adjusted odds ratio, 1.73 [95% CI, 0.61-4.92]; P = .31).
CONCLUSIONS AND RELEVANCE: Among patients who achieved successful reperfusion with EVT for acute ischemic stroke with large vessel occlusion, intensive BP management for 24 hours led to a lower likelihood of functional independence at 3 months compared with conventional BP management. These results suggest that intensive BP management should be avoided after successful EVT in acute ischemic stroke.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04205305.
参考来源
- Nam HS, Kim YD, Heo J, et al. Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial. JAMA. 2023. PMID: 37668619. doi:10.1001/jama.2023.14590
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。